₹67
▼ -6.5 -8.84%
17 Jul 2026
BSE Listed
Asston Pharmaceuticals Limited (544445)
Volume: 1,30,000Avg Vol 1W: 28,600Avg Vol 1M: 25,45552W Range:₹61.02₹126
Key Ratios
Checked just nowMarket Cap—
Current Price₹67
Previous Close₹73.5
High / Low (52w)₹126 / ₹61.02
Volume1,30,000
Avg Vol (1W)28,600
Avg Vol (1M)25,455
Stock P/E—
Book Value—
Dividend Yield—
ROE—
ROA—
Revenue (TTM)—
Revenue Growth—
Profit Margin—
Total Debt—
Shares Outstanding—
Face Value—
EPS (TTM)—
P/B—
Debt / Equity0.77
50 DMA₹77.14
200 DMA₹85.18
Day change-8.84%
Price Chart
₹67▼ 45.75% · 1Y
2025-07-172026-07-17
20-day avg volume: 28K shares
Pros
- Company is almost debt-free.
- Revenue grew 62% YoY.
- Net profit is growing year over year.
Profit & Loss (Annual)
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | ₹11 Cr | ₹7 Cr | ₹16 Cr | ₹26 Cr |
| EBITDA | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹6 Cr |
| Net Profit | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹4 Cr |
| EPS | 11.62 | 1.89 | 2.37 | 6.14 |
Balance Sheet
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | ₹9 Cr | ₹14 Cr | ₹20 Cr | ₹28 Cr |
| Total Liabilities | ₹9 Cr | ₹12 Cr | ₹14 Cr | ₹17 Cr |
| Equity | ₹1 Cr | ₹2 Cr | ₹6 Cr | ₹11 Cr |
| Total Debt | — | — | — | — |
Cash Flow
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating | ₹-1 Cr | ₹0 Cr | ₹-4 Cr | ₹0 Cr |
| Investing | ₹0 Cr | ₹-1 Cr | ₹0 Cr | ₹1 Cr |
| Financing | ₹1 Cr | ₹1 Cr | ₹4 Cr | ₹-1 Cr |
| Free Cash Flow | ₹-1 Cr | ₹0 Cr | ₹-4 Cr | ₹0 Cr |
Shareholding
Promoter 50.66% Institutions 1.91% Public 47.42%
Efficiency & Working Capital
ROCE—
Interest Coverage6.3
Dividend Payout—
Debtor Days358 d
Inventory Days10 d
Payable Days87 d
Cash Conversion Cycle281 d
Working Capital Days368 d
Shareholding Details
As of 2026-03-31
Promoter50.7%
FII1.9%
DII0%
Institutions1.9%
Public47.4%
Promoter Pledge0%
No. of Shareholders687
Shareholding Pattern
Quarterly — figures in %. Latest 5 quarters.
| Period | Jan 2025 | Jun 2025 | Jul 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoters | 69.1% | 50.7% | 50.7% | 50.7% | 50.7% |
| FIIs | 0% | 9.7% | 9.7% | 6% | 1.9% |
| DIIs | 0% | 4.1% | 4.1% | 0% | 0% |
| Public | 30.9% | 35.6% | 35.6% | 43.3% | 47.4% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 104 | 662 | 662 | 751 | 687 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Saili Jayaram More | Shareholding of Promoter and Promoter Group | 21.8% | 18,52,856 |
| Ashish Narayan Sakalkar | Shareholding of Promoter and Promoter Group | 21.8% | 18,52,856 |
| Sachin Chandrakant Badakh | Shareholding of Promoter and Promoter Group | 7.1% | 6,06,768 |
| Mahesh Vishnupant Mulay | Public Shareholding | 2.9% | 2,48,056 |
| Kuldip Singh Rathee | Public Shareholding | 2.4% | 2,00,000 |
| Minerva Ventures Fund | Public Shareholding | 1.9% | 1,63,000 |
| Vrushali Yogesh Supekar | Public Shareholding | 1.5% | 1,24,466 |
| Dilip Rameshchandra Jagad | Public Shareholding | 1.3% | 1,06,672 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Saili Jayaram More | 0 | 0% | 2026-03-31 |
| Ashish Narayan Sakalkar | 0 | 0% | 2026-03-31 |
| Sachin Chandrakant Badakh | 0 | 0% | 2026-03-31 |
| Minerva Ventures Fund | 0 | 0% | 2026-03-31 |
| Kuldip Singh Rathee | 0 | 0% | 2026-03-31 |
| Vrushali Yogesh Supekar | 0 | 0% | 2026-03-31 |
| Mahesh Vishnupant Mulay | 0 | 0% | 2026-03-31 |
| Dilip Rameshchandra Jagad | 0 | 0% | 2026-03-31 |
| Saili Jayaram More | 0 | 0% | 2025-09-30 |
| Ashish Narayan Sakalkar | 0 | 0% | 2025-09-30 |
| Sachin Chandrakant Badakh | 0 | 0% | 2025-09-30 |
| Minerva Ventures Fund | 0 | 0% | 2025-09-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Ashish Narayan Sakalkar | Managing Director | 2025 |
| Saili Jayaram More | Whole Time Director & CEO | 2025 |
| Sachin Chandrakant Badakh | Non Executive Director | 2025 |
| Rishabh Kumar Jain | Independent Non Exe. Director | 2025 |
| Vijaya Shahpurkar | Independent Non Exe. Director | 2025 |
| Vandana Mishra | Company Sec. & Compli. Officer | 2025 |
| Yashvardhan Tupe | Additional Director | 2025 |
| Sandip Sharma | Additional Director | 2025 |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| Export | ₹22 Cr | 86.2% |
| Domestic | ₹3 Cr | 13.8% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 12 | 6 | 6 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 1 | 0 | 3 | 0 | 4 |
| 2025 | 0 | 0 | 0 | 2 | 0 | 2 |
| 2025 | 0 | 1 | 0 | 0 | 0 | 1 |
Company Information
🌐 www.asstonpharmaceuticals.com ↗
📍 4th Flr Office No.A-431 Balaji, Bhavan Plot No.42A Sec-11 CBD, Mumbai, Maharashtra, 400614
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search